 LAVAL, Quebec--BUSINESS WIRE--BELLUS Health Inc. Nasdaq:BLU; TSX:BLU BELLUS Health or the Company, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ending June 30, 2021. Our focus remains on the completion of our two ongoing Phase 2 clinical trials SOOTHE and BLUEPRINT evaluating our selecti 